A historical perspective on the discovery of statins

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 86, Issue 5, 2010, Pages 484-493

  Endo, Akira ^a  

^a Biopharm Research Laboratories Inc   (Japan)

Author keywords

Atherosclerosis; Cholesterol; Cholesterol lowering agent; Coronary heart disease; HMG CoA reductase inhibitor; Statin

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL; ATHEROSCLEROSIS; BIOSYNTHESIS; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; HISTORY; HUMAN; METABOLISM; REVIEW;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; DRUG DISCOVERY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 77955114517     PISSN: 03862208     EISSN: 13492896     Source Type: Journal    
DOI: 10.2183/pjab.86.484     Document Type: Review

References (82)

1. Brown, M.S. and Goldstein, J.L. (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47.
2. Reinitzer, F. (1888) Contributions to the knowledge of cholesterol. Mon. Chem. 9, 421-441.
3. Goldstein, J.L. and Brown, H.S. (2003) Cholesterol: a century of research. HHMI Bull. 16(3), 10-19.
4. Anitschkow, N. (1913) Über die Veränderungen der Kaninchenaorta bei experimenteller Cholesterin-steatose. Beitr. Pathol. Anat. 56, 379-404.
5. Müller, C. (1939) Angina pectoris in hereditary xanthomatosis. Arch. Intern. Med. 64, 675-700.
6. Khachadurian, A.K. (1964) The inheritance of essential familial hypercholesterolemia. Am. J. Med. 37, 402-407.
7. Gofman, J.W., Lindgren, F.T. and Elliott, H. (1949) Ultracentrifugal studies of lipoproteins of human serum. J. Biol. Chem. 179, 973-979.
8. Gofman, J.W., Lindgren, F.T., Elliott, H., Manz, W., Hewitt, J. and Herring, V. (1950) The role of lipids and lipoproteins in atherosclerosis. Science 111, 166-171.
9. Gofman, J.W. (1956) Serum lipoproteins and the evaluation of atherosclerosis. Ann. N.Y. Acad. Sci. 64, 590-595.
10. Keys, A., Anderson, J.T., Fidanza, F., Keys, M.H. and Swahn, B. (1955) Effects of diet on blood lipids in man, particularly cholesterol and lipoproteins. Clin. Chem. 1, 34-52.
11. Keys, A., Aravanis, C., Blackburn, H.W., Van Buchem, F.S., Buzina, R., Djordjević, B.D. et al. (1966) Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Med. Scand. Suppl. 460, 1-392.
12. Keys, A. (1970) Coronary heart disease in seven countries. Circulation 41 (Suppl. 1), 1-211.
13. Kannel, W.B., Dawber, T.R., Kagan, A., Revotskie, N. and Stokes, J., III. (1961) Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann. Intern. Med. 55, 33-50.
14. Wilson, P.W., Garrison, R.J., Castelli, W.P., Feinleib, M., McNamara, P.M. and Kannel, W.B. (1980) Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am. J. Cardiol. 46, 649-654.
15. Bloch, K. (1965) The biological synthesis of cholesterol. Science 150, 19-28.
16. Bucher, N.L., Overath, P. and Lynen, F. (1960) β-Hydroxy-β-methylglutaryl coenzyme A reductase, cleavage and condensing enzymes in relation to cholesterol formation in rat liver. Biochim. Biophys. Acta 40, 491-501.
17. Lynen, F. (1966) The biochemical basis of the biosynthesis of cholesterol and fatty acids. Wien. Klin. Wochenschr. 78, 489-497.
18. Cornforth, J.W. and Popják, G. (1958) Biosynthesis of cholesterol. Br. Med. Bull. 14, 221-226.
19. Popják, G. and Cornforth, J.W. (1960) The biosynthesis of cholesterol. Adv. Enzyme Regul. 22, 281-335.
20. Bloch, K. (1964) Speech at the Nobel Banquet in Stockholm, December 10, 1964.
21. Dietschy, J.M. and Wilson, J.D. (1970) Regulation of cholesterol metabolism. N. Engl. J. Med. 282, 1128-1138.
22. Dietschy, J.M. and Wilson, J.D. (1970) Regulation of cholesterol metabolism. N. Engl. J. Med. 282, 1179-1183.
23. Dietschy, J.M. and Wilson, J.D. (1970) Regulation of cholesterol metabolism. N. Engl. J. Med. 282, 1241-1249.
24. Dietschy, D.M. and Siperstein, M.D. (1967) Effect of cholesterol feeding and fasting on sterol synthesis in seventeen tissues of the rat. J. Lipid Res. 8, 97-104.
25. Dietschy, D.M. and Wilson, J.D. (1968) Cholesterol synthesis in the squirrel monkey: relative rates of synthesis in various tissues and mechanisms of control. Clin. Investig. 47, 166-174.
26. Siperstein, M.D. and Fagan, V.M. (1966) Feedback control of mevalonate synthesis by dietary cholesterol. J. Biol. Chem. 241, 602-609.
27. Steinberg, D. (2006) An interpretive history of the cholesterol controversy, part V. The discovery of the statins and the end of the controversy. J. Lipid Res. 47, 1339-1351.
28. Blohm, T.R. and MacKenzie, R.D. (1959) Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). Arch. Biochem. Biophys. 85, 245-249.
29. Avigan, J., Steinberg, D., Thompson, M.J. and Mosettig, E. (1960) Mechanism of action of MER-29, an inhibitor of cholesterol biosynthesis. Biochem. Biophys. Res. Commun. 2, 63-65.
30. Steinberg, D., Avigan, J. and Feigelson, E.B. (1960) Identification of 24-dehydrocholesterol in the serum of patients treated with MER-29. Prog. Cardiovasc. Dis. 2, 586-592.
31. Avigan, J. and Steinberg, D. (1962) Deposition of desmosterol in the lesions of experimental atherosclerosis. Lancet 1, 527.
32. Altschul, R., Hoffer, A. and Stephen, J.D. (1955) Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. 54, 558-559.
33. Thorp, J.M. and Warig, W.S. (1962) Modification of Metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 194, 948-949.
34. Thompson, G.R. (1989) A Handbook of Hyperlipidemia. Current Science Ltd., London.
35. Bergen, S.S., Jr., Van Itallie, T.B., Tennent, D.M. and Sebrell, W.H. (1959) Effect of an anion exchange resin on serum cholesterol in man. Proc. Soc. Exp. Biol. Med. 102, 676-679.
36. Tennent, D.M., Siegel, H., Zanetti, M.E., Curon, G.W., Ott, W.H. and Wolf, E.J. (1960) Plasma cholesterol lowering action of bile acid binding polymers in experimental animals. J. Lipid Res. 1, 469-473.
37. Koizumi, T. (1939) Hideyo Noguchi (revised). Iwanami Shoten, Tokyo (in Japanese).
38. Okumura, T. (1933) Hideyo Noguchi. Iwanami Shoten, Tokyo (in Japanese).
39. Ludovici, L.J. (1952) Fleming. Discoverer of Penicillin. Andrew Dankers Limited, London.
40. Waksman, S.A. (1954) Living with the Microbes. Simon & Schuster, Inc., New York.
41. Endo, A. (1961) Studies on pectolytic enzymes of molds. I. Survery of enzyme- producing microorganisms by fruit juice clarification. Agr. Biol. Chem. (Japan) 25, 382-388.
42. Endo, A. (1964) Studies on pectolytic enzymes of molds. VIII. Purification and properties of endopolygalacturonase I. Agr. Biol. Chem. (Japan) 28, 535-542.
43. Endo, A. (1964) Studies on pectolytic enzymes of molds. XIII. Clarification of apple juice by the joint action of purified pectolytic enzymes. Agr. Biol. Chem. (Japan) 29, 129-136.
44. Endo, A. (1964) Studies on pectolytic enzymes of molds. XVI. Mechanism of clarfication of apple juice. Agr. Biol. Chem. (Japan) 29, 229-233.
45. Endo, A. and Rothfield, L. (1969) Studies of a phospholipid-requiring bacterial enzyme. I. Purification and properties of UDP-galactose lipopoly-saccharide-α3-galactosyl-transferase. Biochemistry 8, 3500-3507.
46. Endo, A. and Rothfield, L. (1969) Studies of a phospholipid-requiring bacterial enzyme. II. The role of phospholipid in the UDP-galactose: lipopolysaccharide-α3-galactosyl-transferase. Biochemistry 8, 3508-3515.
47. Gale, E.F., Cundliffe, E., Reynold, P.E., Richmond, M.H. and Waring, M.J. (1972) The Molecular Basis of Antibiotic Action. John Wiley & Sons, New York.
48. Goldfarb, S. and Pitot, H.C. (1971) Improved assay of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Lipid Res. 12, 512-515.
49. 14-acetate by rat liver homogenates. J. Am. Chem. Soc. 75, 498.
50. 14-acetate by a rat liver enzyme system. J. Biol. Chem. 234, 2835-2840.
51. Endo, A. and Kuroda, M. (1976) Citrinin, an inhibitor of cholesterol synthesis. J. Antibiot. (Japan) 29, 841-843.
52. Tanzawa, K., Kuroda, M. and Endo, A. (1977) Time-dependent, irreversible inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by the antibiotic citrinin. Biochim. Biophys. Acta 488, 97-101.
53. Endo, A., Kuroda, M. and Tsujita, Y. (1976) ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antibiot. (Japan) 29, 1346-1348.
54. Endo, A. (1988) Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors. Klin. Wochenschr. 66, 421-427.
55. Endo, A. (1992) The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569-1582.
56. Endo, A., Tsujita, T., Kuroda, M. and Tanzawa, K. (1977) Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem. 77, 31-36.
57. Endo, A., Kuroda, M. and Tanzawa, K. (1976) Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML 236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 72, 323-326.
58. Brown, M.S., Dana, S.E. and Goldstein, J.L. (1973) Regulation of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 70, 2162-2166.
59. Brown, M.S. and Goldstein, J.L. (1974) Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc. Natl. Acad. Sci. U.S.A. 71, 788-792.
60. Kaneko, I., Hazama-Shimada, Y. and Endo, A. (1978) Inhibitory effects on lipid metabolism incultured cells of ML-236B, a potent inhibitor of 3-hydroky-3-methylgutaryl-coenzyme-A reductase. Eur. J. Biochem. 87, 313-321.
61. Brown, M.S., Faust, J.R., Goldstein, J.L., Kaneko, I. and Endo, A. (1978) Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem. 253, 1121-1128.
62. Brown, M.S. and Goldstein, J.L. (2004) A tribute to Akira Endo, discoverer of a "penicillin" for cholesterol. Atherosclerosis Suppl. 5, 13-16.
63. Endo, A., Tsujita, Y., Kuroda, M. and Tanzawa, K. (1979) Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim. Biophys. Acta 575, 266-276.
64. Tsujita, Y., Kuroda, M., Tanzawa, K., Kitano, N. and Endo, A. (1979) Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Atherosclerosis 32, 307-313.
65. Kuroda, M., Tsujita, Y., Tanzawa, K. and Endo, A. (1979) Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Lipids 14, 585-589.
66. Brown, A.G., Smale, T.C., King, T.J., Hasenkamp, R. and Thompson, R.H. (1976) Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J. Chem. Soc, Perkin Trans. 1 1165-1170.
67. Fears, R.B, Richards, D.H and Ferres, H. (1980) The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 35, 439-449.
68. Yamamoto, A., Sudo, H. and Endo, A. (1980) Therapeutic effects of ML-236B inprimary hypercholesterolemia. Atherosclerosis 35, 259-266.
69. Abstract Book of the VII International Symposium on Drugs Affecting Lipid Metabolism, held May 28-31, 1980 in Milan, Italy. pp. 224-234.
70. Interview Format in mevastatin (in Japanese). p. 23, Sankyo Co. 1989.
71. Alberts, A.W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C. et al. (1980) Mevinolin: a highly potent competitive inhibitor of hydroxy-methylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 77, 3957-3961.
72. Vagelos, P.R. (1991) Are prescribing drug prices high? Science 252, 1080-1084.
73. Vagelos, P.R. and Galambos, L. (2004) Medicine, Science and Merck. Cambridge University Press, Cambridge, United Kingdom. pp. 1-301.
74. Endo, A. (1979) Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J. Antibiot. 32, 852-854.
75. Brown, M.S., Dana, S.E. and Goldstein, J.L. (1973) Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins. Proc. Natl. Acad. Sci. USA 70, 2162-2166.
76. Brown, M.S., Dana, S.E. and Goldstein, J.L. (1974) Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J. Biol. Chem. 249, 789-796.
77. Mabuchi, H., Haba, T., Tatami, R., Miyamoto, S., Sakai, Y., Wakasugi, T. et al. (1981) Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoprotein and ubiquinone-10-levels in patients with familial hypercholesterolemia. N. Engl. J. Med. 305, 478-482.
78. Mabuchi, H., Sakai, T., Yoshimura, A., Watanabe, A., Wakasugi, T. and Watanabe, A. et al. (1983) Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N. Engl. J. Med. 308, 609-613.
79. Endo, A. (2008) A gift from nature: the birth of the statins. Nat. Med. 14, 1050-1052.
80. Scandinavian Simviastatin Survival Study Group (1994) Randomised trial of cholesterollowering in 4444 patients with coronary heart disease: the Scandinavian Simvistatin Survival Study (4S). Lancet 344, 1383-1389.
81. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., Macfarlane, P.W. et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307.
82. Goldfine, H. and Vance, D.H. (2001) Obituary: Konrad E. Bloch (1912-2000). Nature 409, 779.